Sara Duhachek-Muggy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12050299/publications.pdf

Version: 2024-02-01

933447 1125743 14 319 10 13 citations g-index h-index papers 14 14 14 556 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Radiation mitigation of the intestinal acute radiation injury in mice by 1â€[(4â€nitrophenyl)sulfonyl]â€4â€phenylpiperazine. Stem Cells Translational Medicine, 2020, 9, 106-119.	3.3	16
2	The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 11085-11096.	7.1	33
3	PK-M2-mediated metabolic changes in breast cancer cells induced by ionizing radiation. Breast Cancer Research and Treatment, 2019, 178, 75-86.	2.5	12
4	Serum erythropoietin levels, breast cancer and breast cancer-initiating cells. Breast Cancer Research, 2019, 21, 17.	5.0	14
5	1-[(4-Nitrophenyl)sulfonyl]-4-phenylpiperazine increases the number of Peyer's patch-associated regenerating crypts in the small intestines after radiation injury. Radiotherapy and Oncology, 2019, 132, 8-15.	0.6	8
6	Mebendazole Potentiates Radiation Therapy in Triple-Negative Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 103, 195-207.	0.8	49
7	Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer. Molecular Cancer, 2017, 16, 32.	19.2	39
8	Growth Differentiation Factor 11 does not Mitigate the Lethal Effects of Total-Abdominal Irradiation. Radiation Research, 2017, 188, 549-555.	1.5	0
9	Protein disulfide isomerases in the endoplasmic reticulum promote anchorage-independent growth of breast cancer cells. Breast Cancer Research and Treatment, 2016, 157, 241-252.	2.5	38
10	ADAM12-L is a direct target of the miR-29 and miR-200 families in breast cancer. BMC Cancer, 2015, 15, 93.	2.6	34
11	Phenotypic Diversity of Breast Cancer-Related Mutations in Metalloproteinase-Disintegrin ADAM12. PLoS ONE, 2014, 9, e92536.	2.5	11
12	Metalloproteinase-disintegrin ADAM12 is associated with a breast tumor-initiating cell phenotype. Breast Cancer Research and Treatment, 2013, 139, 691-703.	2.5	24
13	Alternative mRNA Splicing Generates Two Distinct ADAM12 Prodomain Variants. PLoS ONE, 2013, 8, e75730.	2.5	8
14	An essential role of metalloprotease-disintegrin ADAM12 in triple-negative breast cancer. Breast Cancer Research and Treatment, 2012, 135, 759-769.	2.5	33